[go: up one dir, main page]

CL2023001633A1 - Ácidos pirazolo piperidin carboxílicos sustituidos - Google Patents

Ácidos pirazolo piperidin carboxílicos sustituidos

Info

Publication number
CL2023001633A1
CL2023001633A1 CL2023001633A CL2023001633A CL2023001633A1 CL 2023001633 A1 CL2023001633 A1 CL 2023001633A1 CL 2023001633 A CL2023001633 A CL 2023001633A CL 2023001633 A CL2023001633 A CL 2023001633A CL 2023001633 A1 CL2023001633 A1 CL 2023001633A1
Authority
CL
Chile
Prior art keywords
diseases
carboxylic acids
preparation
hypertension
pulmonary
Prior art date
Application number
CL2023001633A
Other languages
English (en)
Inventor
Hernandez Nuria Ortega
Lisa Dietz
Carsten Schmeck
Peter Sandner
Alexandros Vakalopoulos
Marie-Pierre Collin-Kröpelin
Andre Dieskau
Melissa Boultadakis-Arapinis
Lisa Candish
Timo Stellfeld
Ilka Mathar
Lucas Hudson Hofmeister
Frank Wunder
Robert Alan Webster
Thomas Mondritzki
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of CL2023001633A1 publication Critical patent/CL2023001633A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a ácidos pirazolo piperidin carboxílicos sustituidos, sus sales y a procesos para su preparación, y también a su uso para la preparación de medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular enfermedades cardiovasculares y cardíacas, preferiblemente insuficiencia cardíaca con fracción de eyección reducida y conservada (HFrEF, HFmrEF y HFpEF), hipertensión (HTN), enfermedades de arterias periféricas (PAD, PAOD), enfermedades cardiorrenales y renales, preferiblemente enfermedad renal crónica y diabética (CKD y DKD), enfermedades cardiopulmonares y pulmonares, preferiblemente hipertensión pulmonar (PH), y otras enfermedades, preferiblemente enfermedades neurodegenerativas y diferentes formas de demencias, enfermedades fibróticas, esclerosis sistémica (SSc), enfermedad de células falciformes (SCD), trastornos de cicatrización de heridas como la úlcera del pie diabético (DFU)
CL2023001633A 2020-12-10 2023-06-06 Ácidos pirazolo piperidin carboxílicos sustituidos CL2023001633A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20213016.7A EP4011873A1 (en) 2020-12-10 2020-12-10 Substituted pyrazolo piperidine carboxylic acids

Publications (1)

Publication Number Publication Date
CL2023001633A1 true CL2023001633A1 (es) 2023-11-10

Family

ID=73793021

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001633A CL2023001633A1 (es) 2020-12-10 2023-06-06 Ácidos pirazolo piperidin carboxílicos sustituidos

Country Status (19)

Country Link
US (3) US20220274958A1 (es)
EP (2) EP4011873A1 (es)
JP (1) JP7451700B2 (es)
KR (1) KR20230118145A (es)
CN (3) CN118791463A (es)
AR (1) AR124196A1 (es)
AU (2) AU2021393987A1 (es)
CA (1) CA3204491A1 (es)
CL (1) CL2023001633A1 (es)
CO (1) CO2023007334A2 (es)
CR (2) CR20250266A (es)
DO (1) DOP2023000114A (es)
EC (1) ECSP23041151A (es)
GE (2) GEAP202316286A (es)
IL (1) IL303299A (es)
MX (2) MX2023006904A (es)
PE (1) PE20231502A1 (es)
TW (1) TW202237588A (es)
WO (1) WO2022122910A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011874A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
CN116829545A (zh) * 2020-12-10 2023-09-29 拜耳公司 取代的吡唑基哌啶羧酸
EP4011873A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
JP2025518350A (ja) 2022-06-09 2025-06-12 バイエル・アクチエンゲゼルシヤフト 女性における駆出率が維持された心不全の治療に使用するための可溶性グアニル酸シクラーゼアクチベーター
WO2024163561A1 (en) * 2023-01-31 2024-08-08 Invivosciences, Inc. Systems and methods for treating heart failure with preserved ejection fraction
WO2025067414A1 (zh) * 2023-09-27 2025-04-03 海思科医药集团股份有限公司 吡唑羧酸衍生物及其在医药上的应用
TW202535380A (zh) * 2024-01-30 2025-09-16 大陸商海思科醫藥集團股份有限公司 吡唑羧酸衍生物及其在醫藥上的應用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19830431A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Sulfonylamino-carbonsäure-N-arylamide als Guanylatcyclase-Aktivatoren
HU228111B1 (en) 1998-07-08 2012-11-28 Sanofi Aventis Deutschland Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19836697A1 (de) 1998-08-13 2000-02-17 Hoechst Marion Roussel De Gmbh Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19853278A1 (de) 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU2756700A (en) 1999-02-08 2000-08-25 Zymogenetics Inc. Prostate, testis and uterine polypeptide zpep14
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) * 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19944226A1 (de) 1999-09-15 2001-03-29 Aventis Pharma Gmbh Verfahren zum Nachweis von oxidierten Formen der löslichen Guanylatzyklase und Verfahren zum Screening nach Aktivatoren der löslichen Guanylatzyklase mit oxidiertem Hämeisen
JP2003513064A (ja) 1999-11-05 2003-04-08 ユニバーシティ カレッジ ロンドン 可溶性グアニル酸シクラーゼのアクチベーター
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
US20030016677A1 (en) 2001-07-17 2003-01-23 Karl Mauritz Fabric bus architeture
WO2003076408A2 (en) 2002-03-08 2003-09-18 Abbott Laboratories Indazole derivatives that are activators of soluble guanylate cyclase
CA2484089A1 (en) 2002-04-26 2003-11-06 Altana Pharma Ag Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US20040121994A1 (en) 2002-12-20 2004-06-24 Anderson Steven N. Novel amides that activate soluble guanylate cyclase
US20040192680A1 (en) 2002-12-20 2004-09-30 Anderson Steven N. Novel amides that activate soluble guanylate cyclase
GB0318094D0 (en) 2003-08-01 2003-09-03 Pfizer Ltd Novel combination
GB0325291D0 (en) 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
EA201070339A1 (ru) 2007-09-06 2010-10-29 Мерк Шарп Энд Домэ Корп. Активаторы растворимой гуанилатциклазы
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
UY31507A1 (es) 2007-12-03 2009-07-17 Derivados de piridina activadores de guanilato ciclasa soluble
CA2720343A1 (en) 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
WO2010015652A2 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Thiazole compounds as activators of soluble guanylate cyclase
WO2010015653A1 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
JP5501369B2 (ja) 2008-11-25 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化剤
BRPI1008793A2 (pt) 2009-02-26 2016-03-08 Merck Sharp & Dohme composto, uso de um composto, e, composição farmacêutica
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
EP2539326B1 (de) 2010-02-27 2017-05-03 Bayer Intellectual Property GmbH Bis-arylverknüpfte aryltriazolone und ihre verwendung
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2575473B1 (en) 2010-05-27 2016-01-20 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN107021951B (zh) 2010-06-30 2020-10-20 赛克里翁治疗有限公司 sGC刺激物
EP2708539A1 (de) 2010-07-09 2014-03-19 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
US8895583B2 (en) * 2010-10-28 2014-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
ES2572803T3 (es) 2010-11-09 2016-06-02 Ironwood Pharmaceuticals, Inc. Estimuladores de GCs
EP2683710B1 (en) 2011-03-10 2017-07-19 Boehringer Ingelheim International GmbH Soluble guanylate cyclase activators
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
EP2716642B1 (en) 2011-05-30 2016-07-20 Astellas Pharma Inc. Imidazopyridine compound
WO2013025425A1 (en) 2011-08-12 2013-02-21 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
EP3112363A1 (en) 2011-12-27 2017-01-04 Ironwood Pharmaceuticals, Inc. 2-[1-[(2-fluorophenyl)methyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl]-pyrimidine derivatives and related compounds as soluble guanylate cyclase (sgc) stimulators for the treatment of pulmonary hypertension
AU2013312931B2 (en) 2012-09-07 2017-06-22 Boehringer Ingelheim International Gmbh Alkoxy pyrazoles as soluble guanylate cyclase activators
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
WO2014047325A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CN105531690B (zh) 2013-09-27 2018-11-09 英特尔公司 用于确定合适目标的方法、系统及存储介质
WO2015095515A1 (en) 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
JP6623220B2 (ja) 2014-11-03 2019-12-18 バイエル ファーマ アクチエンゲゼルシャフト ヒドロキシアルキル置換フェニルトリアゾール誘導体およびその使用
WO2020245342A1 (en) 2019-06-07 2020-12-10 Bayer Aktiengesellschaft The use of sgc activators for the treatment of ophthalmologic diseases
EP4011873A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
WO2022122914A1 (en) 2020-12-10 2022-06-16 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
CN116829545A (zh) 2020-12-10 2023-09-29 拜耳公司 取代的吡唑基哌啶羧酸
EP4011874A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
KR20230118143A (ko) 2020-12-10 2023-08-10 바이엘 악티엔게젤샤프트 안과 질환의 치료를 위한 sGC 활성화제의 용도

Also Published As

Publication number Publication date
GEP20247635B (en) 2024-06-25
AR124196A1 (es) 2023-02-22
ECSP23041151A (es) 2023-07-31
JP7451700B2 (ja) 2024-03-18
KR20230118145A (ko) 2023-08-10
US20230265072A1 (en) 2023-08-24
EP4259615A1 (en) 2023-10-18
DOP2023000114A (es) 2023-07-09
US20250026737A1 (en) 2025-01-23
CR20250266A (es) 2025-08-27
TW202237588A (zh) 2022-10-01
IL303299A (en) 2023-07-01
CN118787643A (zh) 2024-10-18
CN114981257B (zh) 2024-07-05
US20220274958A1 (en) 2022-09-01
AU2021393987A1 (en) 2023-06-22
WO2022122910A1 (en) 2022-06-16
CN118791463A (zh) 2024-10-18
EP4011873A1 (en) 2022-06-15
AU2021393987A9 (en) 2025-04-03
GEAP202316286A (en) 2023-09-11
CR20230238A (es) 2023-07-19
PE20231502A1 (es) 2023-09-26
CN114981257A (zh) 2022-08-30
MX2025009051A (es) 2025-09-02
MX2023006904A (es) 2023-06-26
CO2023007334A2 (es) 2023-06-09
AU2025279820A1 (en) 2026-01-15
JP2023543646A (ja) 2023-10-18
CA3204491A1 (en) 2022-06-16
US12195448B2 (en) 2025-01-14

Similar Documents

Publication Publication Date Title
CL2023001633A1 (es) Ácidos pirazolo piperidin carboxílicos sustituidos
CL2023001632A1 (es) Ácidos pirazol piperidin carboxílicos sustituidos
Sun et al. Endothelium-mediated contributions to fibrosis
JO3380B1 (ar) مشابهات ابيلين اصطناعية لعلاج قصور القلب
CR20170320A (es) Mezcla de ácidos carboxílicos para tratar pacientes con insuficiencia renal
EA201690278A1 (ru) Циклические полипептиды для лечения сердечной недостаточности
MX2023005736A (es) Compuestos y metodos para modular la expresion de angiotensinogeno.
Summers et al. Pathophysiology of acute decompensated heart failure
Lee et al. A case of reversible very low voltage electrocardiogram in fulminant myocarditis
CN207912198U (zh) 蜂窝鞋垫
Galiuto et al. Functional Tricuspid Regurgitation Repair at the time of Left-Sided Valve Surgery. the Impact on the Cardiac Rehabilitation Program
RU2004105673A (ru) Способ оценки тяжести хронической сердечной недостаточности
Lui et al. Clustering of Systemic Sclerosis-related Pulmonary Hypertension by Global Longitudinal Left Ventricular Strain
Xin et al. Research progress of PDGF-BB/ERK/HIF-1α signaling pathway in hypoxic pulmonary hypertension
CO2025012385A2 (es) Ácidos nucleicos que codifican el atanogén 3 asociado a bcl2 (bag3) para la terapia génica.
Raguindin et al. FP20 The 7 mHz of Love: Assessment of Systolic Function using Bedside Ultrasound of Ten Patients with Chronic Kidney Disease Presenting with Pulmonary Congestion at the Emergency Department of Southern Philippines Medical Center
Dewachter et al. Right Ventricular Failure in Prolonged Overcirculation-Induced PH in Piglets.
Lang et al. Pulmonary Artery Endovascular Device to Improve Vascular Compliance in Pulmonary Hypertension
Yamaguchi et al. Cell death and cardiac remodeling
Nikolaev et al. CHOICE OF MANAGEMENT METHOD OF MYOCARDIAL REVASCULARIZATION IN PATIENTS WITH LOW LEFT VENTRICULAR EJECTION FRACTION (< 35%): A RANDOMIZED PROSPECTIVE STUDY
Zheng et al. Lipoprotein (A) is associated with increased calcification and disease progression in aortic stenosis patients
Byers Local and systemic effects of major traumatic wounds
Oka Molecular Mechanisms of Coronary Angiogenesis in Cardiac Hypertrophy and Failing Heart
MARKER THE TAMILNADU Dr. MGR MEDICAL UNIVERSITY CHENNAI-600 032
Tian et al. Collagen Accumulation Does Not Impair Cardiopulmonary Recovery From Hypoxia, As Assessed Via Admittance Derived Pressure-Volume Loops In Mice